NasdaqGS - Nasdaq Real Time Price • USD
Dynavax Technologies Corporation (DVAX)
At close: April 23 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 5 | 5 |
| Avg. Estimate | -0.02 | 0.09 | 0.25 | 0.5 |
| Low Estimate | -0.06 | 0.03 | 0.15 | 0.29 |
| High Estimate | 0.01 | 0.11 | 0.35 | 0.74 |
| Year Ago EPS | -0.19 | 0.03 | -0.05 | 0.25 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 5 | 5 |
| Avg. Estimate | 54.97M | 78.37M | 287.96M | 347.37M |
| Low Estimate | 50.71M | 76.33M | 273.1M | 314.02M |
| High Estimate | 58.44M | 80M | 301.07M | 376.34M |
| Year Ago Sales | 38.59M | 48.38M | 232.28M | 287.96M |
| Sales Growth (year/est) | 42.40% | 62.00% | 24.00% | 20.60% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.13 | -0.09 | -0.01 | -0.01 |
| EPS Actual | -0.19 | 0.03 | 0.1 | 0 |
| Difference | -0.06 | 0.12 | 0.11 | 0.01 |
| Surprise % | -46.20% | 133.30% | 1,100.00% | 100.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.02 | 0.09 | 0.25 | 0.5 |
| 7 Days Ago | -0.02 | 0.09 | 0.26 | 0.51 |
| 30 Days Ago | -0.02 | 0.09 | 0.26 | 0.51 |
| 60 Days Ago | 0.02 | 0.08 | 0.22 | 0.5 |
| 90 Days Ago | 0.02 | 0.06 | 0.22 | 0.41 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | DVAX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 89.50% | -- | -- | 0.40% |
| Next Qtr. | 200.00% | -- | -- | 9.90% |
| Current Year | 600.00% | -- | -- | 4.30% |
| Next Year | 100.00% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Goldman Sachs: Neutral | 2/1/2024 |
| Maintains | JMP Securities: Market Outperform to Market Outperform | 11/3/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/3/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/4/2023 |
| Maintains | JMP Securities: Outperform to Outperform | 8/4/2023 |
| Maintains | JMP Securities: Outperform | 5/3/2023 |
Related Tickers
DCPH Deciphera Pharmaceuticals, Inc.
14.67
+0.62%
EOLS Evolus, Inc.
11.70
-0.17%
ESPR Esperion Therapeutics, Inc.
2.0900
+9.42%
AVDL Avadel Pharmaceuticals plc
18.09
+4.57%
ELAN Elanco Animal Health Incorporated
13.46
+4.10%
AQST Aquestive Therapeutics, Inc.
4.2800
-2.28%
NBIX Neurocrine Biosciences, Inc.
140.09
+4.81%
IRWD Ironwood Pharmaceuticals, Inc.
8.31
+3.10%
SUPN Supernus Pharmaceuticals, Inc.
29.95
+0.81%
EBS Emergent BioSolutions Inc.
2.2900
+6.02%